Zhaoyang Li

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 25

Top Topics

Hyaluronic Acid

Top Venues

Journal of clinical immunology

Annals of clinical and translational neurology

Immunotherapy advances

Pulmonary therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Zhaoyang Li, Andras Nagy, Dirk Lindner, Kimberly Duff, Enrique Garcia, Hakan Ay, Juan Carlos Rondon, Leman Yel
Tolerability and Safety of Large-Volume Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% Administered with or without Dose Ramp-Up: A Phase 1 Study in Healthy Participants. Journal of clinical immunology 44 (7) (2024)
Hirokazu Kanegane, Akifumi Endo, Satoshi Okada, Hidenori Ohnishi, Masataka Ishimura, Ryuta Nishikomori, Kohsuke Imai, Shigeaki Nonoyama, Hideki Muramatsu, Taizo Wada, Atsushi Kuga, Ko Sakamoto, Sharon Russo-Schwarzbaum, Liang-Hui Chu, Barbara McCoy, Zhaoyang Li, Leman Yel
Pharmacokinetics, safety, and efficacy of 20% subcutaneous immunoglobulin (Ig20Gly) administered weekly or every 2 weeks in Japanese patients with primary immunodeficiency diseases: a phase 3, open-label study. Immunotherapy advances 4 (1) (2024)
Zhaoyang Li, Andras Nagy, Dirk Lindner, Kimberly Duff, Enrique Garcia, Hakan Ay, Juan Carlos Rondon, Leman Yel
Tolerability and Safety of Large-Volume Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% Administered with or without Dose Ramp-Up: A Phase 1 Study in Healthy Participants. Journal of clinical immunology 44 (7) (2024)
Zhaoyang Li, Andras Nagy, Dirk Lindner, Kimberly Duff, Enrique Garcia, Hakan Ay, Juan Carlos Rondon, Leman Yel
Tolerability and Safety of Large-Volume Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% Administered with or without Dose Ramp-Up: A Phase 1 Study in Healthy Participants. Journal of clinical immunology 44 (7) (2024)
Zhaoyang Li, Andras Nagy, Dirk Lindner, Kimberly Duff, Enrique Garcia, Hakan Ay, Juan Carlos Rondon, Leman Yel
Tolerability and Safety of Large-Volume Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% Administered with or without Dose Ramp-Up: A Phase 1 Study in Healthy Participants. Journal of clinical immunology 44 (7) (2024)
Zhaoyang Li, Stefan Roepcke, Ryan Franke, Leman Yel
Dose-exposure-efficacy response of intravenous immunoglobulin G 10% in multifocal motor neuropathy. Annals of clinical and translational neurology 11 (8) (2024)
Zhaoyang Li, Andras Nagy, Dirk Lindner, Kimberly Duff, Enrique Garcia, Hakan Ay, Juan Carlos Rondon, Leman Yel
Tolerability and Safety of Large-Volume Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% Administered with or without Dose Ramp-Up: A Phase 1 Study in Healthy Participants. Journal of clinical immunology 44 (7) (2024)
Zhaoyang Li, Andras Nagy, Dirk Lindner, Kimberly Duff, Enrique Garcia, Hakan Ay, Juan Carlos Rondon, Leman Yel
Tolerability and Safety of Large-Volume Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% Administered with or without Dose Ramp-Up: A Phase 1 Study in Healthy Participants. Journal of clinical immunology 44 (7) (2024)
Hirokazu Kanegane, Akifumi Endo, Satoshi Okada, Hidenori Ohnishi, Masataka Ishimura, Ryuta Nishikomori, Kohsuke Imai, Shigeaki Nonoyama, Hideki Muramatsu, Taizo Wada, Atsushi Kuga, Ko Sakamoto, Sharon Russo-Schwarzbaum, Liang-Hui Chu, Barbara McCoy, Zhaoyang Li, Leman Yel
Pharmacokinetics, safety, and efficacy of 20% subcutaneous immunoglobulin (Ig20Gly) administered weekly or every 2 weeks in Japanese patients with primary immunodeficiency diseases: a phase 3, open-label study. Immunotherapy advances 4 (1) (2024)
Zhaoyang Li, Andras Nagy, Dirk Lindner, Kimberly Duff, Enrique Garcia, Hakan Ay, Juan Carlos Rondon, Leman Yel
Tolerability and Safety of Large-Volume Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% Administered with or without Dose Ramp-Up: A Phase 1 Study in Healthy Participants. Journal of clinical immunology 44 (7) (2024)
Zhaoyang Li, Stefan Roepcke, Ryan Franke, Leman Yel
Dose-exposure-efficacy response of intravenous immunoglobulin G 10% in multifocal motor neuropathy. Annals of clinical and translational neurology 11 (8) (2024)
Zhaoyang Li, Andras Nagy, Dirk Lindner, Kimberly Duff, Enrique Garcia, Hakan Ay, Juan Carlos Rondon, Leman Yel
Tolerability and Safety of Large-Volume Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% Administered with or without Dose Ramp-Up: A Phase 1 Study in Healthy Participants. Journal of clinical immunology 44 (7) (2024)
Zhaoyang Li, Stefan Roepcke, Ryan Franke, Leman Yel
Dose-exposure-efficacy response of intravenous immunoglobulin G 10% in multifocal motor neuropathy. Annals of clinical and translational neurology 11 (8) (2024)
Zhaoyang Li, Andras Nagy, Dirk Lindner, Kimberly Duff, Enrique Garcia, Hakan Ay, Juan Carlos Rondon, Leman Yel
Tolerability and Safety of Large-Volume Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% Administered with or without Dose Ramp-Up: A Phase 1 Study in Healthy Participants. Journal of clinical immunology 44 (7) (2024)
Zhaoyang Li, Stefan Roepcke, Ryan Franke, Leman Yel
Dose-exposure-efficacy response of intravenous immunoglobulin G 10% in multifocal motor neuropathy. Annals of clinical and translational neurology (2024)
Zhaoyang Li, Kristin Follman, Ed Freshwater, Frank Engler, Leman Yel
Effects of Body Mass and Age on the Pharmacokinetics of Subcutaneous or Hyaluronidase-facilitated Subcutaneous Immunoglobulin G in Primary Immunodeficiency Diseases. Journal of clinical immunology (2023)
Andras Nagy, Kimberly Duff, Alexander Bauer, Fred Okonneh, Juan Carlos Rondon, Leman Yel, Zhaoyang Li
A Phase 1 Open-Label Study to Assess the Tolerability, Safety, and Immunogenicity of Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 20% in Healthy Adults. Journal of clinical immunology 44 (1) (2023)
Andras Nagy, Kimberly Duff, Alexander Bauer, Fred Okonneh, Juan Carlos Rondon, Leman Yel, Zhaoyang Li
A Phase 1 Open-Label Study to Assess the Tolerability, Safety, and Immunogenicity of Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 20% in Healthy Adults. Journal of clinical immunology 44 (1) (2023)
Andras Nagy, Kimberly Duff, Alexander Bauer, Fred Okonneh, Juan Carlos Rondon, Leman Yel, Zhaoyang Li
A Phase 1 Open-Label Study to Assess the Tolerability, Safety, and Immunogenicity of Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 20% in Healthy Adults. Journal of clinical immunology 44 (1) (2023)
Andras Nagy, Kimberly Duff, Alexander Bauer, Fred Okonneh, Juan Carlos Rondon, Leman Yel, Zhaoyang Li
A Phase 1 Open-Label Study to Assess the Tolerability, Safety, and Immunogenicity of Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 20% in Healthy Adults. Journal of clinical immunology 44 (1) (2023)
Andras Nagy, Kimberly Duff, Alexander Bauer, Fred Okonneh, Juan Carlos Rondon, Leman Yel, Zhaoyang Li
A Phase 1 Open-Label Study to Assess the Tolerability, Safety, and Immunogenicity of Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 20% in Healthy Adults. Journal of clinical immunology 44 (1) (2023)
Andras Nagy, Kimberly Duff, Alexander Bauer, Fred Okonneh, Juan Carlos Rondon, Leman Yel, Zhaoyang Li
A Phase 1 Open-Label Study to Assess the Tolerability, Safety, and Immunogenicity of Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 20% in Healthy Adults. Journal of clinical immunology 44 (1) (2023)
Andras Nagy, Kimberly Duff, Alexander Bauer, Fred Okonneh, Juan Carlos Rondon, Leman Yel, Zhaoyang Li
A Phase 1 Open-Label Study to Assess the Tolerability, Safety, and Immunogenicity of Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 20% in Healthy Adults. Journal of clinical immunology 44 (1) (2023)
Andras Nagy, Kimberly Duff, Alexander Bauer, Fred Okonneh, Juan Carlos Rondon, Leman Yel, Zhaoyang Li
A Phase 1 Open-Label Study to Assess the Tolerability, Safety, and Immunogenicity of Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 20% in Healthy Adults. Journal of clinical immunology 44 (1) (2023)
Zhaoyang Li, Ryan M Franke, Denise N Morris, Leman Yel
Pharmacokinetics and Biochemical Efficacy of an α 1 -Proteinase Inhibitor (Aralast NP) in α 1 -Antitrypsin Deficiency: a Cross-Product Retrospective Comparability Analysis. Pulmonary therapy 8 (3) (2022)